Business Wire

LINTONPHARM

1.12.2021 14:02:14 CET | Business Wire | Press release

Share
LintonPharm Announces First Patient Dosed in Phase 1 Clinical Trial of Catumaxomab for Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin

LintonPharm Co., Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T cell engaging bispecific antibodies for cancer immunotherapy, today announced that the first patient has been dosed in the Company’s Phase 1/2 clinical trial program for catumaxomab (clinicaltrials.gov: NCT04799847 ), a monoclonal bispecific antibody being studied for the treatment of Non-Muscle-Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).

“The initiation of our Phase 1 trial of catumaxomab for the treatment of NMIBC is an important step in our clinical program evaluating catumaxomab as targeted therapy in a broad range of cancers”, said Robert Li, PH.D., DABT, Co-founder and CEO of LintonPharm. “Patients with NMIBC BCG failure need new therapies due to the limitations of current treatments which bring poor prognosis, such as high rates of tumor recurrence, bladder dysfunction and lifelong intervention. Based on encouraging pre-clinical data and clinical experience with patients who’ve received catumaxomab in the past through the compassionate use program, we are hopeful that catumaxomab will be a very promising immunotherapy candidate for patients with NMIBC BCG failure.”

A recent publication indicated clinical benefits of catumaxomab as compassionate use in patients with EpCAM-positive recurrent NMIBC. It is noted that catumaxomab was well tolerated and presented promising performance in tumor control [1] . Based on the data and the developmental potential, catumaxomab could provide a feasible, safe, and efficacious therapy for NMIBC patients, if approved.

Bladder cancer is the 10th most commonly diagnosed cancer worldwide, with approximately 573,000 new cases in 2020 and roughly 75 percent are diagnosed as NMIBC [2][3] . Currently, the mainstay treatments of NMIBC include transurethral resection, chemotherapy and intravesical BCG [3] .

About Catumaxomab

Catumaxomab was approved by the European Medicines Agency in 2009 for the treatment of malignant ascites. This bispecific antibody binds to a transmembrane glycoprotein on the tumor cell--the epithelial cell adhesion molecule (EpCAM)--and CD3 on the T cell, and also recruits immune accessory cells through FcγR binding. Catumaxomab destroys tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects which has been verified in animal models.

Recently, catumaxomab was authorized by regulatory authorities in China, Taiwan (China) and South Korea to conduct a global Phase 3 clinical trial for treating patients with advanced gastric cancer (clinicaltrials.gov: NCT04222114 ).

About LintonPharm

LintonPharm Co., Ltd. is a clinical-stage, research-oriented biopharmaceutical company committed to developing innovative T cell engaging bispecific antibodies with the goal of turning malignant cancers into manageable and possibly curable diseases. LintonPharm has developed multiple bispecific antibody platforms with a great potential of refined safety and efficacy profiles, long-lasting vaccinal effects and CMC efficiency. The current pipeline includes several treatments in development for blood cancer and solid tumors. The leading molecule, catumaxomab is being evaluated in clinical trials for both advanced gastric cancer and non-muscle invasive bladder cancer. For more information, please visit www.lintonpharm.com .

[1]. Ruf P, Bauer HW, Schoberth A, Kellermann C, Lindhofer H (2021). First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non muscle invasive bladder cancer indicates high tolerability and local immunological activity. Cancer Immunology, Immunotherapy. http://doi.org/10.1007/s00262-021-02930-7

[2]. World Health Organization (WHO). Globocan 2020. Global Cancer Observatory. Accessed January 7, 2021. https://gco.iarc.fr/

[3]. Kamat AM, Hahn NM, Efstathiou JA, et al. (2016) Bladder cancer. Lancet 2016. 388: 2796-810. http://dx.doi.org/10.1016/S0140-6736(16)30512-8

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Windrose and Autel Validate Real-World Megawatt Charging Under MCS Standard in the Netherlands17.3.2026 09:03:00 CET | Press release

As electric heavy-duty vehicles continue to expand across Europe, charging infrastructure is evolving toward megawatt-level capability. Windrose and Autel Europe recently announced the successful completion of a real-world Megawatt Charging System (MCS) charging session at the Mega Charging Hub of a prime customer of Revolt in Roosendaal, marking an operational validation of charging under the MCS standard in live site conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260313298350/en/ Windrose electric truck charging with Autel’s MCS-enabled megawatt charging system. The deployment features a modular megawatt configuration combining three MaxiCharger DS480 high-power charging cabinets connected in parallel to form a 1,440 kW system. The setup is paired with the MaxiCharger DT1500 MCS-enabled dispenser, capable of delivering up to 1.2 MW output through the MCS interface with a maximum current of 1,500 A, while also s

Aqara Enhances Smart Home Security Lineup with Camera Hub G350, and the Doorbell Camera G400 (Wired)17.3.2026 09:00:00 CET | Press release

Aqara offered a unified, comprehensive home security experience to users with the world’s first Matter-certified camera and the reliable wired camera Aqara, a global leader and pioneer in IoT, today announced the availability of the Camera Hub G350, the world’s first Matter-certified camera, and the Doorbell Camera G400 (Wired), expanding its next-generation smart home security lineup. Together, these new products deliver seamless interoperability, intelligent monitoring, and comprehensive home coverage for the modern smart home. Camera Hub G350: World’s First Matter-Certified Camera and Smart Home Controller The Aqara Camera Hub G350 marks an important milestone for Aqara as the world’s and the company’s first Matter-certified camera. Built to deliver future-ready interoperability, the G350 connects directly to Matter-enabled platforms* while offering live view, two-way audio, and alerts within the Matter-enabled ecosystem. Beyond serving as an indoor security camera, the device also

Yolanthe Cabau Honoured With Lifetime Achievement Award for Her Global Fight Against Child Sexual Exploitation17.3.2026 09:00:00 CET | Press release

The actress, entrepreneur and philanthropist was recognised during UN Commission on the Status of Women Week for nearly two decades of advocacy with her foundation, Free a Girl During the United Nations Commission on the Status of Women Week, actress, entrepreneur and philanthropist, Yolanthe Cabau, was awarded the Lifetime Achievement Award from the New York City Bar Association in recognition of her work combating the sexual exploitation of children. Held in New York, the awards evening emphasised the importance of safety within the justice system, recognising that protecting vulnerable children also requires safeguarding the frontline teams working to create change. As the founder of the anti-child sex trafficking NGO Free a Girl, the Lifetime Achievement Award recognises Cabau’s eighteen years of dedication to rescuing children from sexual exploitation worldwide and supporting their path to justice, recovery, and empowerment. Free a Girl is a women-led organisation working to comba

Mobileum Showcases “Signal to Value” at MWC Barcelona 202617.3.2026 09:00:00 CET | Press release

AI-driven capabilities across roaming, fraud and risk management, network assurance, and enterprise AI help operators turn network events into insight, action, and revenue Mobileum Inc. (“Mobileum”), a leading global provider of analytics and network solutions, highlighted its ”Signal to Value” vision at MWC Barcelona 2026, demonstrating how telecom operators can turn network events into insight, action, and revenue. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317260292/en/ Mobileum team at MWC Barcelona 2026. At the event, Mobileum demonstrated how operators can leverage its Active Intelligence Platform to enhance roaming performance, strengthen fraud and risk defenses, and automate network assurance across increasingly complex global networks. “Operators generate massive volumes of network events every second, but the real value comes from turning those events into insights, action, and revenue,” said Bernardo Lucas,

SIAL Paris 2026 : the Event That Sheds Light on and Accelerates the Global Food Business17.3.2026 09:00:00 CET | Press release

SIAL Pariswill return to Paris Nord Villepinte from 17 to 21 October 2026. The 2026 edition is set to be the most ambitious in the show’s history, surpassing an already record-breaking 2024 event and further cementing its status as a global benchmark for the food industry. SIAL Paris once again positions itself as a powerful business accelerator, an unparalleled showcase for major innovations and a strategic observatory of the trends shaping the future of food worldwide. With 85% of exhibition space already booked, up to 8,000 exhibitors expected, 295,000 professionals and more than 280,000 m² of exhibition space spanning 10 key sectors, SIAL Paris 2026 confirms both its exceptional international reach and the strong commitment of companies across the entire food value chain. A STRONG COMMERCIAL DYNAMIC AND A HIGHLY INTERNATIONAL SHOW Seven months ahead of opening, SIAL Paris 2026 is already posting strong commercial indicators. More than 260,000 m² of exhibition space has been sold, r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye